Mylan Head Of Biologics Chrys Kokino On Fulphila Launch And US Biosimilars
Executive Summary
Mylan's Kokino spoke with Scrip about what he called the successful launch of the company's first biosimilar in the US, a version of Amgen's Neulasta, the state of the US biosimilar market and resetting expectations.
You may also be interested in...
Mylan Sees Generic Advair Marathon Nearing FDA Finish Line
Company management expressed confidence its application for the first generic Advair is approvable, although the US agency didn’t clear it in October as Mylan had hoped.
Mylan Sees Generic Advair Marathon Nearing FDA Finish Line
Company management expressed confidence its application for the first generic Advair is approvable, although the US agency didn’t clear it in October as Mylan had hoped.
Pharma Q3 Preview: Amgen, Allergan, Pfizer, GSK And Sanofi
Pfizer CEO Ian Read will preside over his last sales and earnings call as the big pharma's chief executive, while for GlaxoSmithKline, uncertainty lingers over the timing of a generic Advair. Amgen will have its second opportunity to talk to investors about its 60% Repatha price cut, while answering questions about Aimovig strategy and Neulasta biosimilars. And other topics to watch in the next earnings calls...